FAQs
What is the standard induction therapy for AML?
The standard induction therapy, known as the 7+3 regimen, involves seven days of continuous cytarabine infusion combined with three days of an anthracycline such as daunorubicin or idarubicin, aimed at achieving complete remission.
How do AML treatment guidelines address older adults?
For patients over 60 years, guidelines recommend lower intensity regimens like Low-Intensity 5+2 (cytarabine plus anthracycline) or azacitidine/decitabine combined with venetoclax to balance treatment efficacy and toxicity.
What role do targeted therapies play in AML treatment?
Targeted therapies such as FLT3 inhibitors, IDH1/2 inhibitors, and venetoclax-based combinations are incorporated based on genetic mutation testing to improve outcomes and offer alternatives to intensive chemotherapy.
When is an allogeneic stem cell transplant recommended in AML?
Allogeneic stem cell transplant (alloSCT) is generally recommended for patients with high-risk cytogenetics or persistent minimal residual disease after consolidation therapy to reduce relapse risk.
How often are AML treatment guidelines updated?
Guidelines from bodies like NCCN, ASH, and ELN are updated every 2 to 3 years to reflect advances in drugs, genetic insights, and clinical experience, with the latest NCCN update released in early 2024.
